While atrial fibrillation is a well-known risk of BTK inhibitors, the more devastating and less-discussed risk is sudden death from ventricular arrhythmias. This is an 'on-target' class effect, making AFib just the 'tip of the iceberg' of cardiovascular toxicity.
While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.
CLL-associated immunosuppression dramatically increases the risk and aggressiveness of skin cancers. This risk is not mitigated by novel therapies, and in some cases, the secondary skin malignancy can become a greater threat to a patient's life than their underlying CLL.
While standard guidelines dictate treating only symptomatic CLL, some patients experience debilitating anxiety from 'watch and wait.' In rare cases, clinicians may initiate therapy primarily to improve quality of life by removing this significant psychological stress.
With pirtobrutinib, time to next treatment often exceeds progression-free survival. This discrepancy exists because disease progression is frequently slow and asymptomatic, meaning clinicians do not need to switch therapies immediately upon seeing radiographic changes, allowing for longer treatment duration.
BTK inhibitors function as highly potent antiplatelet agents, an 'on-target' effect. Many surgeons are unaware, leading to significant post-operative bleeding if the drug isn't stopped. Patients must be educated to inform their surgical teams and advocate for themselves.
While pirtobrutinib is effective after covalent BTK inhibitors, the reverse is unproven. Starting with pirtobrutinib frontline raises a critical unanswered question about whether patients will still respond to older covalent inhibitors, complicating sequencing decisions, especially for younger patients.
A common assumption that older patients may prefer simpler, continuous medication regimens is often incorrect. Clinical experience shows that the vast majority of patients, regardless of age, are interested in a time-limited therapy option, provided it can be delivered conveniently without infusions.
Current fixed-duration CLL regimens are not MRD-guided, so the test result does not alter the treatment plan. While a negative result is prognostically favorable, its main clinical utility is to provide reassurance. A detectable result can cause unnecessary patient anxiety.
BTK degraders work despite most kinase inhibitor resistance mutations. However, resistance to degraders themselves alters the BTK binding pocket so significantly that subsequent targeting with any BTK kinase inhibitor is unlikely to be effective, positioning them as a potential end-of-line therapy.
BTK inhibitors like ibrutinib can improve T-cell function. When combined with liso-cel CAR-T, this synergistic effect dramatically improves outcomes in heavily pretreated patients, increasing the complete response rate from 20% to 45% and the overall response rate from 48% to 86%.